At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed Mar 16, 2026 at 16:04 ET
CytomX Therapeutics announced a public offering of $250.0 million in common stock and pre-funded warrants, with an additional $37.5 million option for underwriters to purchase more shares. The offering is expected to dilute existing shareholders and is subject to market conditions.
- CytomX announced a public offering of $250.0 million in common stock and pre-funded warrants.
- Underwriters have a 30-day option to purchase up to an additional $37.5 million in shares.
- All securities are being offered directly by CytomX, indicating primary issuance and not a secondary sale.
- Proceeds will likely be used for general corporate purposes, R&D, or clinical trial funding, though specific use was not detailed in the release.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access